Enlitic Announces Strategic Partnership With Select Healthcare Solutions
16 October 2019 - 1:48AM
Business Wire
—Leading Medical AI Software Company and
U.S. Cancer Center Operator Partner to Further Advance Early
Detection and Characterization of Various Cancers—
Enlitic, Inc., a leading developer of artificial intelligence
software designed to help doctors diagnose patient conditions more
quickly and more accurately, announced today that it has signed a
strategic partnership with Select HealthCare Solutions, a
developer, owner, and operator of world-class cancer centers across
the U.S. As part of the agreement, Enlitic will receive access to
Select Healthcare’s high-quality, anonymized patient data––data
that will further tune Enlitic’s predictive models for early cancer
detection. In turn, Select HealthCare will receive access to
Enlitic’s best-in-class software technology and will directly
contribute to the development of future Enlitic products in
radiology, oncology and pathology.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20191015006184/en/
Enlitic is transforming medical
diagnostics with artificial intelligence. (Graphic: Business
Wire)
Enlitic’s deep learning models have demonstrated amazing
potential for the early detection of malignancies. In an
independent validation study from 2017, Enlitic's algorithm was
found to detect lung nodules with 91.1% sensitivity at time of
biopsy, operating on par with state-of-the-art CAD, but with much
higher specificity. Furthermore, the algorithm was shown to detect
malignancies 6 and 12 months before biopsy, and reliably caught
cancerous nodules 17.5 months earlier than when a biopsy was
ordered.
Enlitic’s partnership with Select HealthCare adds to the
company’s global partnership roster of leading healthcare and
technology companies, including Capitol Health, a leading
Australian healthcare provider; Marubeni Corporation, a Japan-based
global conglomerate; and Konica Minolta, a leading multi-national
technology company also based in Japan.
“Oncology presents some of the most meaningful needs for
clinical AI, but with solutions that can only be built with the
right data and the right expertise,” said Kevin Lyman, Enlitic’s
Chief Executive Officer. “Select HealthCare’s data will drastically
accelerate our research into the early detection of most forms of
cancer and their clinical expertise will help drive our development
of best-in-class workflow solutions for oncology centers around the
world.”
“Enlitic’s diagnostic AI software is crucial to improving
patient care in the future and we are excited to join the company’s
list of world-class partners by providing comprehensive multi-modal
data that will help revolutionize how cancer is detected and
treated,” said Matthew Cutler, President and Chief Executive
Officer of Select HealthCare Solutions. “We believe that our
clinical experience in treating complex cancers, combined with
Enlitic’s best-in-class technologies and experience in early
disease detection, will ultimately help save millions of
lives.”
About Select HealthCare Solutions LLC
Select HealthCare Solutions is a San Diego-based developer of
state-of-the-art cancer centers across the United States. The
company provides a total solution for financing, development, and
operation of facilities in partnership with its physician-partners.
Select HealthCare’s physicians are globally recognized for their
work in oncology and their combined experience treating millions of
cancer patients. For more information, visit selecthcs.com.
About Enlitic
Named one of the world’s “50 Smartest Companies” by MIT
Technology Review, Enlitic is a pioneer in medical deep learning,
building a best-in-class platform that bridges human and artificial
intelligence to save time, money, and ultimately, lives. The
company’s team of practicing radiologists, data scientists, and
software engineers analyze a vast stream of healthcare data ––
including millions of clinical cases from cross-sector healthcare
partners –– to improve diagnostic accuracy, speed, and patient
outcomes, as well as to accelerate pharmaceutical research and drug
trials. Enlitic is based in San Francisco and has offices in New
York and Sydney, Australia. Find out more at enlitic.com, and
follow the company on Twitter, and Linkedin.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191015006184/en/
John Ordoña jordona@enlitic.com